Vanguard Group Inc. Grows Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vanguard Group Inc. increased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,665,210 shares of the company’s stock after purchasing an additional 158,376 shares during the period. Vanguard Group Inc. owned 6.68% of Recursion Pharmaceuticals worth $154,459,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Deutsche Bank AG grew its holdings in Recursion Pharmaceuticals by 15.4% in the third quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock worth $457,000 after purchasing an additional 7,973 shares during the period. Federated Hermes Inc. purchased a new position in Recursion Pharmaceuticals during the third quarter valued at $153,000. Alps Advisors Inc. boosted its holdings in Recursion Pharmaceuticals by 10.5% in the third quarter. Alps Advisors Inc. now owns 156,214 shares of the company’s stock worth $1,195,000 after acquiring an additional 14,818 shares in the last quarter. Citigroup Inc. grew its stake in shares of Recursion Pharmaceuticals by 165.3% in the third quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock worth $3,599,000 after acquiring an additional 293,174 shares during the last quarter. Finally, Green Alpha Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 96.5% during the fourth quarter. Green Alpha Advisors LLC now owns 67,871 shares of the company’s stock valued at $669,000 after acquiring an additional 33,329 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total value of $87,684.02. Following the sale, the director now owns 7,229,861 shares in the company, valued at $55,380,735.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the sale, the director now owns 7,229,861 shares in the company, valued at $55,380,735.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Tina Marriott sold 3,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $8.78, for a total value of $26,340.00. Following the completion of the transaction, the chief operating officer now directly owns 535,457 shares in the company, valued at $4,701,312.46. The disclosure for this sale can be found here. Insiders sold 207,359 shares of company stock valued at $1,704,435 over the last three months. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Trading Up 2.7 %

Recursion Pharmaceuticals stock opened at $7.35 on Friday. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $16.75. The stock has a fifty day simple moving average of $8.81 and a two-hundred day simple moving average of $9.88. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -4.59 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period last year, the company earned ($0.34) EPS. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.